CGT

830개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved830 programs
CGTStandard DatabasestaleHebei Senlang Biotechnology Inc…Phase 2

Autologous BCMA-targeting CAR T cells (Autologous BCMA-targeting CAR T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleInstituto de Investigación Hosp…Phase 1

Autologous CD19/CD22 CAR T cells (Autologous CD19/CD22 CAR T cells)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
CGTLimited DatastaleKara Lynn DavisPhase 1

Autologous CD22 CAR T (Autologous CD22 CAR T)

B Cell Lymphoma; Acute Lymphoblastic Leukemia, Pediatric · CD22

#CD22#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 30Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

BCMA-CART cells (BCMA-CART cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
CGTLimited DatastaleShanghai Simnova Biotechnology …Phase 1

CAR-NK-CD19 Cells (CAR-NK-CD19 Cells)

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 30Status Active
CGTStandard DatabasestaleYake Biotechnology Ltd.Phase 2

CAR-T cells targeting CD19 and CD22 (CAR-T cells targeting CD19 and CD22)

B-Cell Acute Lymphoblastic Leukemia, Adult · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

CD19/CD20 CAR-T cell infusion (CD19/CD20 CAR-T cell infusion)

CAR · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
CGTLimited DatastaleAlex's Lemonade Stand FoundationPhase 1

GD2 CAR T cells (GD2 CAR T cells)

Neuroblastoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTStandard DatabasestaleBOE Technology Group Co., Ltd.Phase 2

NK cells + PD- (NK cells + PD-, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy)

NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer · NSCLC (Advanced Non-small Cell Lung Canc

#NSCLCAdvancedNon-smallCellLungCa#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Preclinical

T cell injection targeting CD19 chimeric antigen receptor (T cell injection targeting CD19 chimeric antigen receptor)

Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Active
CGTStandard DatabasestaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

anti-CD19 CAR-NK (anti-CD19 CAR-NK)

NHL · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
CGTLimited DatastaleHrain Biotechnology Co., Ltd.Preclinical

anti-CD19-CAR vector-transduced T cells (anti-CD19-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 30Status Active
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Lymphoma, B-Cell · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleBeijing Bio-Targeting Therapeut…Phase 2

oncolytic virus (oncolytic virus)

Glioblastoma (GBM) · Glioblastoma (GBM)

#GlioblastomaGBM#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 30Status Recruiting
CGTLimited DatastaleGlycostem Therapeutics BVPhase 1

umbilical cord blood NK cells (umbilical cord blood NK cells)

Neuroblastoma · Soft Tissue Sarcoma (STS)

#SoftTissueSarcomaSTS#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 1

anti-CD19/CD22 CAR-T cells (anti-CD19/CD22 CAR-T cells)

MRD-positive; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 28Status Active
CGTLimited DatastaleGracell Biotechnology Ltd.Phase 1

BCMA/CD19 Dual-Target CAR-T (BCMA/CD19 Dual-Target CAR-T)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 27Status Active
CGTLimited DatastaleDompé Farmaceutici S.p.APhase 1

Ex-Vivo expanded autologous IL-8 receptor (CXCR2, Ex-Vivo expanded autologous IL-8 receptor, Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)

Brain Metastases · Glioblastoma Multiforme

#GlioblastomaMultiforme#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 25Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

Breast Cancer (Advanced/Metastatic); HER2-positive Breast Cancer · Malignant Glioma

#MalignantGlioma#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 23Status Recruiting

6 / 42 pages

← PreviousNext →